Department of Urology, Foch Hospital, Suresnes, France.
Patients with end-stage renal disease (ESRD) are at risk of developing renal tumours.
Objective: Compare clinical, pathologic, and outcome features of renal cell carcinomas (RCCs) in ESRD patients and in patients from the general population.
Twenty-four French university departments of urology participated in this retrospective study.
All patients were treated according to current European Association of Urology guidelines.
Age, sex, symptoms, tumour staging and grading, histologic subtype, and outcome were recorded in a unique database. Categoric and continuous variables were compared by using chi-square and student statistical analyses. Cancer-specific survival (CSS) was assessed by Kaplan-Meier and Cox methods.
The study included 1250 RCC patients: 303 with ESRD and 947 from the general population. In the ESRD patients, age at diagnosis was younger (55±12 yr vs 62±12 yr); mean tumour size was smaller (3.7±2.6cm vs 7.3±3.8cm); asymptomatic (87% vs 44%), low-grade (68% vs 42%), and papillary tumours were more frequent (37% vs 7%); and poor performance status (PS; 24% vs 37%) and advanced T categories (≥3) were more rare (10% vs 42%). Consistently, nodal invasion (3% vs 12%) and distant metastases (2% vs 15%) occurred less frequently in ESRD patients. After a median follow-up of 33 mo (range: 1-299 mo), 13 ESRD patients (4.3%), and 261 general population patients (27.6%) had died from cancer. In univariate analysis, histologic subtype, symptoms at diagnosis, poor PS, advanced TNM stage, high Fuhrman grade, large tumour size, and non-ESRD diagnosis context were adverse predictors for survival. However, only PS, TNM stage, and Fuhrman grade remained independent CSS predictors in multivariate analysis. The limitation of this study is related to the retrospective design.
RCC arising in native kidneys of ESRD patients seems to exhibit many favourable clinical, pathologic, and outcome features compared with those diagnosed in patients from the general population.
Written by:
Neuzillet Y, Tillou X, Mathieu R, Long JA, Gigante M, Paparel P, Poissonnier L, Baumert H, Escudier B, Lang H, Rioux-Leclercq N, Bigot P, Bernhard JC, Albiges L, Bastien L, Petit J, Saint F, Bruyere F, Boutin JM, Brichart N, Karam G, Branchereau J, Ferriere JM, Wallerand H, Barbet S, Elkentaoui H, Hubert J, Feuillu B, Theveniaud PE, Villers A, Zini L, Descazeaux A, Roupret M, Barrou B, Fehri K, Lebret T, Tostain J, Terrier JE, Terrier N, Martin L, Dugardin F, Galliot I, Staerman F, Azemar MD, Irani J, Tisserand B, Timsit MO, Sallusto F, Rischmann P, Guy L, Valeri A, Deruelle C, Azzouzi AR, Chautard D, Mejean A, Salomon L, Rigaud J, Pfister C, Soulié M, Kleinclauss F, Badet L, Patard JJ. Are you the author?
Reference: Eur Urol. 2011 Mar 2. Epub ahead of print.
doi: 10.1016/j.eururo.2011.02.035
PubMed Abstract
PMID: 21377780
UroToday.com Renal Cancer Section
